Treatment Of Metastatic Castration-resistant Prostate Cancer With Abiraterone And Docetaxel

Objective:To analyze and compare the clinical efficacy and safety of abiraterone acetate combined with prednisone+androgen deprivation therapy(ADT)and docetaxel combined with prednisone+androgen deprivation therapy(ADT)in the treatment of metastatic castration-resistant prostate cancer(mCRPC)in Xinjiang area.Methods:Retrospective analysis of clinical data of mCRPC patients admitted to urology department of 7 hospitals in Xinjiang area from June 2016 to January 2018.The abiraterone group was treated with abiraterone acetate(1000mg/qd)combination with prednisone(5mg/bid)+ADT for a total of 46 patients;The docetaxel group was treated with docetaxel(75mg/m~2 three weeks at a time,a total of 10 times)combined with prednisone(5mg/bid)+ADT for a total of 48 patients.The primary endpoint was radiographic progression-free survival(rPFS)and prostate specific antigen progression-free survival(PSA PFS).Results:The median follow-up time was 15 months,and the median radiographic progression-free survival(rPFS)was 15 months and 11 months in the abiraterone and docetaxel groups respectively.Median prostate specific antigen progression-free survival(PSA PFS)in the abiraterone and docetaxel groups was 13months and 9 months respectively.The PSA response rate was 63.04%in the abiraterone group and 41.67%in the docetaxel group.In terms of safety,the proportion of 3-5 grade adverse reactions was 45.65%in the abiraterone group and 47.92%in the docetaxel group.The proportion of 3-5 grade adverse reactions was similar,but the adverse drug reactions involved were different,consistent with the drug descriptions and known adverse reactions.Conclusions:Compared with docetaxel plus prednisone+ADT,abiraterone acetate combined with prednisone+ADT improved rPFS,PSA PFS and increased PSA response rate.In terms of adverse reactions,there was no significant difference between the two treatment regimens.